The efficacy of radiotherapy with adjuvant temozolomide for glioblastoma remains controversial. We conduct a systematic review and meta-analysis to explore the influence of radiotherapy with adjuvant temozolomide on treatment efficacy for glioblastoma.We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through November 24, 2019 for randomized controlled trials (RCTs) assessing the efficacy and safety of adjuvant temozolomide to radiotherapy for glioblastoma. This meta-analysis is performed using the random-effect model.Five RCTs are included in the meta-analysis. Overall, compared with radiotherapy for glioblastoma, adjuvant temozolomide is associated with substantially improved overall survival (HR = 0.63; 95% CI = 0.52-76; P < 0.00001) and 2-year survival rate (3.25 = 1.76; 95% CI = 2.13-4.94; P < 0.00001), with no increase in adverse events (RR = 0.76; 95% CI = 0.40-1.45; P = 0.41). However, adjuvant temozolomide appears to increase the incidence of haematological complications than only radiotherapy (RR = 3.58; 95% CI = 1.10-11.59; P = 0.03).Adjuvant temozolomide to radiotherapy may provide better efficacy for the treatment of glioblastoma.

中文翻译：

---

替莫唑胺辅助放疗治疗胶质母细胞瘤的疗效和安全性：随机对照研究的荟萃分析

辅助替莫唑胺放疗对胶质母细胞瘤的疗效仍存在争议。我们进行了一项系统回顾和荟萃分析，以探讨辅助替莫唑胺放疗对胶质母细胞瘤治疗效果的影响。我们在 PubMed、EMbase、Web of science、EBSCO 和 Cochrane 图书馆数据库中搜索截至 2019 年 11 月 24 日的随机对照试验 ( RCTs）评估辅助替莫唑胺对胶质母细胞瘤放疗的疗效和安全性。该荟萃分析使用随机效应模型进行。荟萃分析中包括五项随机对照试验。总体而言，与胶质母细胞瘤放疗相比，替莫唑胺辅助治疗可显着提高总生存率（HR = 0.63；95% CI = 0.52-76；P < 0.00001）和 2 年生存率（3.25 = 1.76；95% CI = 2.13） -4.94；P < 0.00001），不良事件没有增加（RR = 0.76；95% CI = 0.40-1.45；P = 0.41）。然而，辅助替莫唑胺似乎比单纯放疗增加了血液学并发症的发生率（RR = 3.58；95% CI = 1.10-11.59；P = 0.03）。替莫唑胺辅助放疗可能为胶质母细胞瘤的治疗提供更好的疗效。